Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

AX3 ® Bio-Pure Astaxanthin Extends Lifespan in NIH-Funded Longevity Study


News provided by

AX3 Life

Dec 06, 2023, 15:00 ET

Share this article

Share toX

Share this article

Share toX

Groundbreaking research from the Interventions Testing Program represents major advance in longevity field

HONOLULU, Dec. 6, 2023 /PRNewswire-PRWeb/ -- AX3 Life, a human longevity company, announced breakthrough life extension findings related to its longevity supplement, AX3® Bio-Pure Astaxanthin—a highly bioavailable, pure, and environmentally sustainable form of astaxanthin that safely fights inflammaging and other hallmarks of aging to improve lifespan and healthspan.

AX3® Bio-Pure Astaxanthin was evaluated in an important longevity study conducted by the Interventions Testing Program (ITP), a peer-reviewed program supported by the National Institute on Aging (NIA), part of the National Institutes of Health (NIH). The ITP is widely recognized as the gold standard in longevity research and uses lifespan as its primary endpoint. Conducting lifespan studies in humans would require decades, so the ITP's rigorous testing of lifespan in laboratory mice represents the most credible and practical assessment of mammalian lifespan presently available.

Results of the multi-year ITP study demonstrated that AX3® Bio-Pure Astaxanthin extended the median lifespan of male mice by 12% with strong statistical significance (p=0.003). Dosing started when the mice were middle aged and showed a consistent survival benefit versus control animals throughout their lifespans. Astaxanthin has also been shown to increase lifespan in several non-mammalian model organisms (yeast, roundworms, fruit flies), and the ITP has now extended such findings to mammals (mice).

"This study provides a new pathway in the quest to advance human longevity, because astaxanthin is the first agent in the ITP's 20-year history to demonstrate a greater than 10% increase in lifespan that is also exceptionally safe for chronic use and broadly accessible as a dietary supplement," said Dave Watumull, AX3 Life Co-Founder and CEO and co-author of the GeroScience paper reporting these findings. "This study underscores why astaxanthin, and in particular AX3® Bio-Pure Astaxanthin, should be a key part of everyone's longevity regimen."

Full study results were published on December 2, 2023, in GeroScience, a premier, peer-reviewed journal that publishes cutting-edge research related to the biology of aging. Top-line study results were presented earlier this year by AX3 Life at the ONEFUTURE summit on Sir Richard Branson's Necker Island.

"After 25 years of working to advance the research and development of astaxanthin, we are thrilled to see astaxanthin's utility for longevity demonstrated in this very reputable, independent study," said David Watumull, AX3 Life Co-Founder and co-author of the above-referenced paper in GeroScience. "Our mission is to help people live longer, healthier lives, and if you extrapolate these results to humans, it could translate to a median lifespan increase of nearly a decade, showing the power astaxanthin may have to transform lives."

Research reported in this news release was supported by the NIA, part of the NIH, under award numbers U01AG022303, U01AG022307, U01AG022308, and U24AG066346. The content is solely the responsibility of the authors and does not represent the official views of the NIH. The NIH is the nation's medical research agency—making important discoveries that improve health and save lives.

About Astaxanthin

Astaxanthin is a naturally occurring supernutrient with profound antioxidant and anti-inflammatory health benefits. It supports health and vitality throughout the marine environment and even powers salmon's swim upstream. More than 3,000 peer-reviewed papers have been published on astaxanthin, and its safety and efficacy have been studied in more than 50 human clinical studies and hundreds of animal studies.

About AX3

AX3 Life (Honolulu, Hawaii) is a human longevity company that's changing the way we age. The company's flagship product—AX3® Bio-Pure Astaxanthin—is a longevity supplement that safely fights inflammaging and other hallmarks of aging to improve lifespan and healthspan. Inspired by nature and perfected with science, AX3® Bio-Pure Astaxanthin is produced via natural product total synthesis, providing superior purity, bioavailability, and environmental sustainability compared with ordinary astaxanthin. It's time to Age Fearlessly®.

About the ITP

The Interventions Testing Program (ITP) is a peer-reviewed program designed to identify agents that extend lifespan and healthspan in mice. The ITP is supported by the National Institute on Aging (NIA), part of the National Institutes of Health (NIH). Testing is carried out simultaneously at three sites—the University of Michigan, the Jackson Laboratory, and the University of Texas Health Science Center at San Antonio. The three testing sites work closely with the NIA to design and execute a consistent experimental protocol. Each site also brings specialized expertise to the project, including statistical analysis, pharmacology, toxicology, optimal diet compounding, and non-harmful tests of age-sensitive physiological function.

Media Contact

Jaya Jaya Myra Productions Inc.

Myra Godfrey

Publicist

[email protected]

Jaya Jaya Myra Productions Inc.

Desmond Warren

Senior PR Associate

[email protected]

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Hundreds of scientific studies support astaxanthin's health benefits, as reviewed by Fakhri S. et al. "Astaxanthin: A mechanistic review on its biological activities and health benefits." Pharmacological Research, 2018, 136: 1-20. doi:10.1016/j.phrs.2018.08.012. For more information, please visit: ax3.life/science

Media Contact

Myra Godfrey, Jaya Jaya Myra Productions, 1 3474764358, myra@jayajayamyraproductions.com

SOURCE AX3 Life

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.